
ACTU Stock Forecast & Price Target
ACTU Analyst Ratings
Bulls say
Actuate Therapeutics Inc. demonstrates a promising outlook due to the strong efficacy displayed by its lead compound, elraglusib, which significantly improved the 12-month overall survival rate from 22.3% to 44.4% in combination with gemcitabine/nab-paclitaxel, thus indicating a highly favorable treatment response in difficult-to-treat cancers. The potential for expedited market entry, should a positive decision on a comprehensive market application (CMA) be granted, could enhance revenue projections by reducing the time to commercialization for elraglusib by 18 months. Furthermore, Actuate's strategy to seek non-dilutive funding through grants and investigator-initiated trials could mitigate financial risks associated with advancing its clinical programs, positioning the company for sustained growth as it expands its development pipeline into additional indications.
Bears say
Actuate Therapeutics Inc faces a negative outlook primarily due to the overall market sentiment surrounding oncology drugs, despite some positive decisions for similar therapies. The company is experiencing a reduction in projected financial performance, as indicated by a lowered price target, suggesting a reevaluation of the anticipated success and potential revenue from elraglusib. Additionally, while elraglusib’s data may appear strong, it is critical to note that the competitive landscape includes therapies that have also received positive evaluations, potentially diluting Actuate's market position.
This aggregate rating is based on analysts' research of Actuate Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
ACTU Analyst Forecast & Price Prediction
Start investing in ACTU
Order type
Buy in
Order amount
Est. shares
0 shares